UWM lab crunches data to seek mysterious gravitational waves
Two UW stem-cell patents upheld

Third Wave trials a success

By JUDY NEWMAN 608-252-6156

Third Wave Technologies has hit a major milestone, and at least one expert is predicting it will send the Madison biotechnology company's stock soaring today.

Third Wave said Tuesday it has completed human clinical trials on its test for the human papillomavirus (HPV), often a precursor of cervical cancer. More than 3,400 women were screened at 47 sites and Third Wave's test, which screens for 14 high-risk types of HPV, demonstrated a 99 percent likelihood that women with a negative test result do not have cervical disease, the company said.

The results will be submitted to the U.S. Food and Drug Administration in April.

Full story.

Please visit our sponsor Gehrke & Associates, SC to learn more about how to enhance and defend your intellectual property.  Thank you.